<DOC>
	<DOCNO>NCT00711880</DOCNO>
	<brief_summary>The purpose study evaluate efficacy Sativex® compare placebo relieve peripheral neuropathic pain associate allodynia .</brief_summary>
	<brief_title>A Study Sativex® Relief Peripheral Neuropathic Pain Associated With Allodynia .</brief_title>
	<detailed_description>This six week , multicentre , double blind , randomise , placebo control parallel group study evaluate efficacy Sativex® . Subjects peripheral neuropathic pain characterise allodynia , screen determine eligibility enter seven day baseline period . Subjects return centre randomisation dose introduction , receive either placebo Sativex double blind manner five week , follow visit 7 10 day end treatment period . The primary efficacy measure difference pain severity end treatment , measure use peripheral neuropathic pain 0 10 numerical rating scale .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Hyperalgesia</mesh_term>
	<criteria>Willing able give inform consent . Male female , age 18 year . Chronic peripheral neuropathic pain least six month duration . Presence mechanical allodynia within territory affect nerve ( ) . Evidence sensory change affect nerve simple clinical test . Peripheral neuropathic pain severity score four least four complete NRS baseline week . Stable dose analgesic medication least two week lead study entry . Agreement , female child bear potential male partner child bearing potential , ensure effective contraception use study three month thereafter . Have use cannabinoids ( include cannabis , Marinol Nabilone ) least seven day Visit 1 willing abstain use cannabinoids study . Ability ( investigator 's opinion ) willingness comply study requirement . Agreement UK Home Office , primary care physician , consultant appropriate , notify participation study . History schizophrenia , psychotic illness , severe personality disorder significant psychiatric disorder depression associate underlying condition . Concomitant severe nonneuropathic pain presence cancer relate neuropathic pain neuropathic pain result diabetes mellitus . Known history alcohol substance abuse . Severe cardiovascular disorder , ischaemic heart disease , arrhythmia ( well control atrial fibrillation ) , poorly control hypertension severe heart failure . History epilepsy . If female , pregnant lactating , plan pregnancy occur course study . Significant renal hepatic impairment . Elective surgery procedure require general anaesthesia schedule occur study . Terminal illness consider inappropriate placebo medication . Any significant disease disorder , opinion investigator , may either put subject risk participation study , may influence result study , subject 's ability participate study . Regular levodopa ( Sinemet® , Sinement Plus® , Levodopa® , Ldopa® , Madopar® , Benserazide® ) therapy within seven day lead study entry . If male , receive unwilling stop sildenafil ( Viagra® ) duration study . Known suspect hypersensitivity cannabinoids excipients study medication . Known suspect adverse reaction cannabinoids . Intention travel internationally study . Intention donate blood study . Participation another research study 12 week lead study entry . Previous randomisation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Pain</keyword>
	<keyword>Peripheral Neuropathy</keyword>
</DOC>